Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma

Acta Pharmacologica Sinica

Volumn 27, Issue 12, 2006, Pages 1642-1646

  Xu, Wen ^a   Sun, Jin ^a   Zhang, Ting Ting ^a   Ma, Bo ^a   Cui, Sheng Miao ^b   Chen, Da Wei ^a   He, Zhong Gui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Intraperitoneal injections; Intravenous; Oral bioavailability; Oridonin; Pharmacokinetics; Rats

Indexed keywords

ORIDONIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MEAN RESIDENCE TIME; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DITERPENES; DITERPENES, KAURANE; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MALE; PLANTS, MEDICINAL; RABDOSIA; RATS; RATS, WISTAR;

EID: 33751361646     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2006.00440.x     Document Type: Article

References (19)

1. Yuan K, Yang ZH, Yang Y, Zhang XM, Sun W. Determination of oridonin in Rabdosia rubescences by HPLC. Henan Sci 1998; 16: 175-7. Chinese.
2. Zuo HJ, Li D, Wu B, Gao HY, Wu LJ, Ikejima T. Studies on the constituents of Rabdosia rubescens (Hemsl) Hara and their antitumor activities in vitro. J Shenyang Pharm Univ 2005; 22: 258-62. Chinese.
3. Guan YZ, Wei TH. Clinical research on the oridonin injection for the interventional therapy of liver cancer. J Med Radiol Technol 2005; 236: 43. Chinese.
4. Wang RL. Clinical evaluation of Rabdosia rubescences for 31 patients with liver cancer. Chin J Cancer 1984; 8: 50. Chinese.
5. Henan Research Group for Rabdosia rubescences. Conclusion of clinical evaluation of Rabdosia rubescences for the treatment of 68 patients with esophageal carcinoma and carcinoma of gastric cardia. Cancer Res Prev Treat 1976; 3: 32-3. Chinese.
6. Zhang DR, Ren TC, Lou HX, Xing J. The tissue distribution in mice and pharmacokinetics in rabbits of oridonin-solid lipid nanoparticles. Acta Pharm Sin 2005; 40: 573-6. Chinese.
7. 3H]rubescensine A in mice. Acta Pharmacol Sin 1983; 4: 57-60. Chinese.
8. Xu W, Sun J, Zhang TT, Tang JL, Li HY, Fang JL, et al. A rapid and accurate HPLC/ESI-MS method for the quantitative determination of oridonin in rat plasma. Pharmazie 2006; 61: 757-9.
9. Zhang YB, Kou X, Lu JS, Wang GH. Study on the inclusion of oridonin-β-cyclodextrin. J Chin Med Mater 1999; 22: 204-5. Chinese.
10. Jepson MA, Clark MA, Hirst BH. M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery. Adv Drug Deliv Rev 2004; 56: 511-25.
11. Liu JJ, Wu XY, Peng J, Pan XL, Lu HL. Antiproliferation effects of oridonin on HL-60 cells. Ann Hematol 2004; 83: 691-5.
12. Heish TC, Wijeratne EK, Liang JY, Gunatilaka AL, Wu JM. Differential control of growth, cell cycle progression, and expression of NF-κB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the Chinese herb Rabdosia rubescens. Biochem Biophys Res Commun 2005; 337: 224-31.
13. Ren KK, Wang HZ, Xie LP, Chen DW, Liu X, Sun J, et al. The effects of oridonin on cell growth, cell cycle, cell migration and differentiation in melanoma cells. J Ethnopharmacol 2006; 103: 176-80.
14. Chen S, Gao J, Halicka HD, Huang X, Traganos F, Darzynkiewicz Z. The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int J Oncol 2005; 26: 579-88.
15. Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H, et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther 2005; 4: 578-86.
16. Huang J, Wu L, Tashiro S, Onodera S, Ikejima T. A comparison of the signal pathways between the TNF alpha- and oridonin-induced murine L929 fibrosarcoma cell death. Acta Med Okayama 2005; 59: 261-70.
17. Wang RL, Fan KS, Fan QX, Ji ZC, Yue BY, Chen ST, et al. Clinical evaluation for 437 esophageal carcinoma patients. Chin J Integrat Tradit West Med 1989; 9: 740-1. Chinese.
18. Xu SY, Bian RL, Chen X. Methodology for pharmacological experiments, 3rd ed. Beijing: People's Medical Publishing House; 2001.
19. Cai RC, Guo HF. Clinical research of Donglingcao combined with UFT for the treatment of advanced lung cancer. Prac Clin J Integr Tradit Chin Western Med 2003; 3: 12-3. Chinese.